Blackstone Credit & Insurance announced it is leading a $1.3 billion financing to support the combination of Paratek Pharmaceuticals and Radius Health, creating a scaled, multi-asset specialty pharmaceutical company.
The transaction brings together two complementary organizations backed by B-FLEXION Life Sciences and advances Paratek’s strategy of building a platform focused on high-need, targeted therapeutic areas. The combined company will have a diversified portfolio of innovative medicines and is positioned for long-term growth.
Paratek is expected to generate nearly $1 billion in annual revenue in 2026, reflecting the scale and breadth of the combined platform. The financing highlights continued momentum in private credit and structured capital solutions within healthcare and life sciences, as firms back consolidation strategies and platform expansion.
The newly combined company will integrate commercial-stage assets with lifecycle management and clinical development initiatives aimed at strengthening and expanding its portfolio across multiple therapeutic areas.
KEY QUOTES
“We are pleased to support B-FLEXION and management in the creation of a scaled specialty pharmaceutical platform. This transaction reflects our ability to provide large-scale capital solutions to life sciences companies.”
Jonathan Brayman, Managing Director, Blackstone Credit & Insurance
“We are proud to partner with Blackstone on this next phase of growth for Paratek, as it is a transformative transaction for both the organization and the broader platform. This also represents an exciting next step in Paratek’s ability to serve patients and communities across a growing number of therapeutic areas.”
Peter Agnes, Operating Partner, B-FLEXION Life Sciences
